Evidence map›Paper›PMID 32392373›Full record

ArticleClinical pharmacology and therapeutics2020

Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Self-Controlled Case Series Study.

Young Hee Nam, Xu Han, Colleen M Brensinger, Warren B Bilker, Charles E Leonard, Sean Hennessy

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Young Hee NamDepartment of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Xu HanDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Colleen M BrensingerDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Warren B BilkerDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Charles E LeonardDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5092-9657
Sean HennessyDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4726-9413

Funding

Clinical Importance of Drug-Drug InteractionsR01AG025152 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, LI, LANG · 2006 to 2021
$8.1M
Drug interactions involving psychoactive drugsR01AG060975 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Charles Edward Leonard · 2019 to 2026
$3.9M
Drug-Drug Interactions Involving Methadone and BuprenorphineR01DA048001 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN · 2019 to 2023
$2.9M
Drug-Drug Interactions Involving Antidiabetic AgentsR01DK102694 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HENNESSY, SEAN, LI, LANG · 2014 to 2017
$2.4M
NIA NIH HHS R01 AG025152NIA NIH HHS R01 AG060975NIDA NIH HHS R01 DA048001NIDDK NIH HHS R01 DK102694
6 · The paper itself

Abstract

Drug interactions between warfarin and sulfonylureas are suggested by pharmacokinetic information and prior studies. However, clinical evidence on the association of such interactions and the risk of bleeding is lacking. Using healthcare claims data from 5 US Medicaid programs from 1999-2011 and a self-controlled case series design with warfarin as an object drug, we calculated confounder-adjusted rate ratios (RRs) for concomitant use of sulfonylureas and metformin for 3 outcomes separately: (i) serious bleeding as a composite outcome of gastrointestinal bleeding (GIB) and nontraumatic intracranial hemorrhage (ICH); (ii) GIB; and (iii) ICH. In 6,463 warfarin users experiencing serious bleeding, an increased rate of serious bleeding was not associated with concomitant use of glimepiride (RR: 0.93; 95% confidence interval (CI) 0.75-1.15), glipizide (RR: 0.97; 95% CI 0.84-1.13), glyburide (RR: 0.89; 95% CI 0.76-1.06), or metformin (RR: 0.85; 95% CI 0.76-0.96), nor was the occurrence of the component outcomes of GIB or ICH. These results suggest that use of sulfonylureas or metformin was not associated with an increased rate of serious bleeding in warfarin users.

Indexed as

AdolescentAdultAgedAged, 80 and overAnticoagulantsDrug InteractionsFemaleHemorrhageHumansHypoglycemic AgentsMaleMedicaidMetforminMiddle AgedRisk AssessmentRisk FactorsAnticoagulantsHypoglycemic AgentsMetforminSulfonylurea CompoundsWarfarin

Identifiers

PMID32392373
PMCPMC7788336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.